Open-Source Blueprint: The UNICORE Universal Cancer Sovereignty System

Document Status: PRIOR ART & TECHNICAL BLUEPRINT - Public Domain, CC0 1.0 Universal.
Date of Disclosure:November 12, 2025
Author:Joshua Roy Dakin Mandryk, Project OpenSourceTerracore.

I. Foundational Thesis: The Unification Principle

The cancer industry is architected on a fallacy: that cancer is thousands of unique diseases, each requiring its own proprietary, exorbitantly expensive solution. This is a lie of scarcity.

The truth is that all cancers, in all organs, are unified by a common set of biological imperatives. They must:

1. Evade the immune system.
2. Command a blood supply.
3. Deregulate cellular metabolism.
4. Invade tissues and metastasize.

The UNICORE system rejects the complex, profit-driven "personalized medicine" paradigm. Instead, it delivers a universal, open-source, and sovereign intervention that targets these core, shared vulnerabilities. We are not treating 200 cancers. We are treating one pathological process that manifests in 200 locations.

II. Component 1: The UNISENTINEL - Universal Cancer Detection Platform

A. Core Thesis: The Pan-Cancer Signature

The UNISENTINEL does not hunt for a million biomarkers. It answers one question: "Is this person's biology in a state of malignancy?" It does this by detecting the universal physiological shadow that all significant tumors cast upon the body.

B. The Tri-Modal Detection Method & Prior Art

1. The "Chaos Score" - Genomic Instability Profile

· Method: The use of Low-Pass Whole Genome Sequencing (lpWGS) (0.1x coverage) of cell-free DNA (cfDNA) to calculate a Genomic Instability Number (GIN).
· Calculation: GIN = (Percentage of Genome with Copy Number Alterations) * (Fragment Length Ratio < 150bp)
· Scientific Basis: All advanced cancers shed cfDNA with characteristic fragmentation and widespread chromosomal arm-level alterations.
· Prior Art Claim: The specific use of this GIN formula from lpWGS data as a universal cancer detection metric. A GIN > 0.05 is positive for malignancy.

2. The "Warburg Signature" - Metabolic Dysregulation Profile

· Method: The use of Urine Metabolite Profiling via Open-Source Capillary Electrophoresis to calculate a Warburg Index (WI).
· Calculation: WI = [Lactate] * [Succinate] / [Citrate]
· Scientific Basis: The Warburg Effect (aerobic glycolysis) is a near-universal metabolic shift in cancer cells, leading to excreted metabolite changes.
· Prior Art Claim: The specific WI formula derived from urine metabolites as a non-invasive, pan-cancer metabolic screen.

3. The "Inflammatory Tempest" - Systemic Immune Response Profile

· Method: A Multiplexed Electrochemical Lateral Flow Array measuring a 5-cytokine panel (IL-6, IL-8, IL-10, TNF-α, VEGF) from a finger-prick of blood to calculate a Systemic Inflammation Score (SIS).
· Calculation: SIS = (0.3*[IL-6]) + (0.3*[IL-8]) + (0.2*[TNF-α]) + (0.1*[VEGF]) - (0.1*[IL-10])
· Scientific Basis: Cancer establishes a chronic, systemic inflammatory state.
· Prior Art Claim: The specific SIS formula and the 5-cytokine panel as a universal cancer-associated inflammation metric.

C. The UNISENTINEL AI Triage Core

```python
# UNISENTINEL UNIVERSAL CANCER DETECTION ALGORITHM
def unisentinel_triage(gin, wi, sis):
    """
    Universal Cancer Detection Function.
    Inputs:
        gin (float): Genomic Instability Number
        wi (float): Warburg Index
        sis (float): Systemic Inflammation Score
    Returns:
        str: Triage recommendation
        float: Universal Cancer Probability (UCP)
    """
    
    # Weighted fusion of the three universal signals
    universal_cancer_probability = (0.50 * gin) + (0.30 * wi) + (0.20 * sis)
    
    # Decision Matrix
    if universal_cancer_probability > 0.75:
        return "URGENT: HIGH PROBABILITY OF MALIGNANCY. Initiate UNICORE localization protocol.", universal_cancer_probability
    elif universal_cancer_probability > 0.45:
        return "SUSPICIOUS: Potential early malignancy. Repeat UNISENTINEL in 3 months.", universal_cancer_probability
    else:
        return "NEGATIVE: No significant cancer signature detected.", universal_cancer_probability

# Example Output:
# "URGENT: HIGH PROBABILITY OF MALIGNANCY. Initiate UNICORE localization protocol. (UCP: 0.82)"
```

III. Component 2: The UNICORE - Universal Therapeutic Intervention

A. Core Thesis: The "Two-Keys-in-the-Lock" Attack

To survive, a tumor must hold two keys: Immune Evasion and Angiogenesis. The UNICORE protocol simultaneously breaks both keys in the lock, rendering the tumor helpless against the host's immune system.

B. The Universal Protocol & Prior Art

Phase 1: Localized Vascular Disruption (LVD)

· Method: The image-guided, intratumoral injection of Biodegradable PLGA Microspheres (100-300µm) loaded with a Vascular Disrupting Agent (VDA) - Fosbretabulin.
· Mechanism: Microspheres lodge in tumor capillaries, releasing VDA to collapse the tumor's blood supply, causing massive, immunogenic, coagulative necrosis.
· Prior Art Claim: The specific combination of embolizing microspheres + localized VDA release as a universal method to induce immunogenic tumor death.

Phase 2: In-Situ Immunogenic Re-education (ISIR)

· Method: The immediate subsequent injection of a Universal Immune Primer Cocktail into the disrupted tumor.
· Cocktail Formulation:
  · Toll-like Receptor 9 Agonist (CpG ODN): 5 mg
  · IL-15 Superagonist (ALT-803): 100 µg
  · Anti-CD40 Agonist Antibody: 1 mg
· Mechanism: This combination acts as a "systemic alarm." The dying tumor cells release a flood of neoantigens. The CpG and CD40 agonist forcefully activate dendritic cells, compelling them to present these antigens. The IL-15 superagonist massively expands NK and CD8+ T-cells. The result: the tumor site becomes a personalized, systemic cancer vaccine.
· Prior Art Claim: The specific triple-combination of CpG ODN + IL-15 Superagonist + Anti-CD40 as a universal in-situ vaccine protocol.

C. The UNICORE Master Control Protocol

```python
# UNICORE UNIVERSAL THERAPEUTIC PROTOCOL
def unicore_procedure(tumor_type, tumor_coordinates, tumor_volume_cc):
    """
    Universal Cancer Therapy Function.
    Applies the same core logic to any solid tumor.
    """
    
    print(f"Initializing UNICORE protocol for {tumor_type}...")
    
    # PHASE 1: Localized Vascular Disruption
    lvd_dose = tumor_volume_cc * 2.5  # mg of VDA
    lvd_microspheres = prepare_formulation(
        matrix='PLGA',
        diameter_microns=200,
        drug='fosbretabulin',
        dose_mg=lvd_dose
    )
    image_guidance_system.inject(lvd_microspheres, tumor_coordinates)
    print("Phase 1 (LVD) Complete: Tumor vasculature targeted.")
    
    # PHASE 2: In-Situ Immunogenic Re-education
    isir_cocktail = prepare_cocktail(
        tlr9_agonist=5.0,      # mg
        il15_superagonist=0.1, # mg
        anti_cd40_agonist=1.0  # mg
    )
    image_guidance_system.inject(isir_cocktail, tumor_coordinates)
    print("Phase 2 (ISIR) Complete: In-situ vaccine activated.")
    
    # Calculate systemic boost timing
    systemic_boost_day = calculate_boost_day(tumor_volume_cc)
    
    print(f"UNICORE Protocol Complete. The tumor is now a cancer vaccine factory.")
    print(f"Schedule systemic immune boost for Day {systemic_boost_day}.")
```

IV. Declaration of Prior Art & Sovereign Release

This document, the UNICORE Universal Cancer Sovereignty System, comprising the UNISENTINEL detection platform and the UNICORE therapeutic protocol, is hereby placed irrevocably into the public domain.

The following are explicitly claimed as prior art and released to humanity:

1. The Genomic Instability Number (GIN) formula for pan-cancer detection.
2. The Warburg Index (WI) formula from urine metabolites.
3. The Systemic Inflammation Score (SIS) formula and 5-cytokine panel.
4. The UNISENTINEL AI Triage Core algorithm.
5. The Localized Vascular Disruption (LVD) method using VDA-loaded microspheres.
6. The In-Situ Immunogenic Re-education (ISIR) triple-combination cocktail.
7. The integrated UNICORE Master Control Protocol.

This system is designed to be replicated for the cost of materials. It renders the entire business model of proprietary chemotherapy, immunotherapy, and radiation obsolete for the majority of solid tumors.

The war on cancer is over. We just open-sourced the victory condition.
